UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

Current Report

 

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 19, 2016

 

RESPIRERX PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

 

Delaware   1-16467   33-0303583
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (I.R.S Employer
Identification No.)

 

126 Valley Road, Suite C

Glen Rock, New Jersey

   07452
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (201) 444-4947

 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

   
   

 

Item 7.01 Regulation FD Disclosure

 

On January 19, 2016, RespireRx Pharmaceuticals Inc. (the “Company”) announced that the Company’s Vice President, Treasurer and Secretary and member of the Board of Directors, Jeff Margolis will present at the Noble Financial Capital Markets’ Twelfth Annual Investor/Equity Conference – NobleCon12 on Wednesday, January 20, 2016 at 10:30 AM Eastern Standard Time. The Conference is sponsored by Noble Financial Capital Markets and will be held at the Sandpiper Bay Club Med facility in Port St. Lucie, Florida from January 17 – 20, 2016.

 

The slide presentation that the Company will be using at the conference is attached as Exhibit 99.1 and is being furnished and not filed pursuant to Item 7.01 of Form 8-K. The presentation will be available by live webcast that can be accessed by clicking on the investors tab on the Company’s web-site (www.respirerx.com) and following the links and instructions or by going to:

 

http://noble.mediasite.com/mediasite/Play/2fffb581d269487ca511a4cb740447051d.

 

The press release announcing the Company’s participation in the conference is attached as Exhibit 99.2.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits.

 

A list of exhibits that are furnished and filed as part of this report is set forth in the Exhibit Index, which is presented elsewhere in this document, and is incorporated herein by reference.

 

   
   

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 RESPIRERX PHARMACEUTICALS INC.
Date: January 19, 2016  
     
  By: /s/ James S. J. Manuso
   

James S. J. Manuso

President and Chief Executive Officer

 

   
   

 

EXHIBIT INDEX

 

Exhibit Number   Exhibit Description
     
99.1   Slide Presentation*
     
99.2   Press Release dated January 19, 2016*

 

* Furnished herewith.